Innoviva Completes Acquisition of Entasis Therapeutics
BURLINGAME, Calif.–(BUSINESS WIRE)–Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc. (“Entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products. Entasis brings to Innoviva an exciting portfolio that includes … [Read more…]